Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: A randomized study.
Asselah TarikStanislas PolChristophe HezodeVeronique Loustaud-RattiVincent LeroySi Nafa Si AhmedViolaine OzenneJean-Pierre BronowickiDominique LarreyAlbert TranLaurent AlricEric Nguyen-KhacMichael N RobertsonGeorge J HannaDeborah BrownErnest Asante-AppiahFeng-Hsiu SuPeggy HwangJessie Durrand HallAmir GuidoumKarin HagenBarbara A HaberRohit TalwaniLawrence SerfatyPublished in: Liver international : official journal of the International Association for the Study of the Liver (2020)
These data confirm the efficacy of elbasvir/grazoprevir administered for 12 weeks in treatment-experienced individuals with HCV GT4 infection and those with advanced fibrosis. Treatment-naive individuals with mild fibrosis can be treated effectively with an 8-week regimen.